Semaglutide (Wegovy) for Obesity and Heart Disease | How a New Injection Could Reshape NHS Prevention Strategy

The UK NHS plan to scale up use of semaglutide (Wegovy) for up to 1.2 million people sits on strong clinical evidence that this GLP‑1 agonist can both reduce obesity and lower future cardiovascular risk. In the landmark SELECT trial of 17,604 adults with prior cardiovascular disease, overweight/obesity but no diabetes, weekly semaglutide 2.4 mg reduced major cardiovascular events (cardiovascular death, non‑fatal heart attack or non‑fatal stroke) by 20% over about 3.5 years compared with placebo, on top of standard care.

Long‑term analysis from the same trial shows sustained weight loss of about 10% at four years, with parallel reductions in waist circumference and waist‑to‑height ratio across all BMI categories. Exploratory analyses from the STEP 1 and STEP 4 obesity trials confirm that semaglutide improves multiple cardiometabolic risk factors blood pressure, LDL and non‑HDL cholesterol, fasting glucose and insulin resistance and allows some patients to reduce antihypertensive and lipid‑lowering medications.

Real‑world studies show similar patterns: 12 months of semaglutide in clinical practice produced average weight loss of 13–17% and significant improvements in blood pressure, lipids and overall cardiovascular risk scores. Population modelling using US data suggests that if all eligible adults received semaglutide, obesity prevalence could fall by 46% and 10‑year cardiovascular events by ~18%, preventing an estimated 1.5 million events

These findings explain why semaglutide is now being positioned not only as a weight‑loss drug but as a secondary‑prevention therapy for high‑risk patients with obesity and established cardiovascular disease. Yet scaling this treatment to more than a million NHS patients raises major clinical, logistical and economic challenges. Gastrointestinal side‑effects (nausea, vomiting, diarrhoea) are common and cause drug discontinuation in 10–20% of patients in trials; in SELECT, adverse events led to permanent discontinuation in 16.6% of those on semaglutide versus 8.2% on placebo .

Systematic review and meta‑analysis across 38 studies confirm cardiovascular benefits reductions in heart‑failure hospitalisation (‑76%), cardiovascular death (‑17%), all‑cause death (‑21%), myocardial infarction (‑24%) and coronary revascularisation (‑24%) but also higher relative risk of most adverse effects, particularly gastrointestinal problems. Observational data from routine care show that weight and risk‑factor improvements tend to reverse after stopping semaglutide, with two‑thirds of lost weight regained and cardiometabolic gains lost, indicating that long‑term or even lifelong therapy may be needed to maintain benefi. This has profound implications for NHS budgets and drug supply. Commentary from technology‑assessment bodies such as CADTH in Canada has already questioned reimbursement because early trials did not yet prove hard outcomes like fewer heart attacks or strokes and raised doubts about cost‑effectiveness if benefits are limited to weight loss and modest quality‑of‑life gains

SELECT and newer analyses now fill that gap for secondary prevention, but cost, prioritisation and equity issues remain central. Real‑world cohort work in older insured populations finds about an 8% overall cardiovascular risk reduction with modern anti‑obesity drugs such as semaglutide and tirzepatide, but also highlights that users are typically sicker, highly comorbid and dependent on complex insurance and monitoring pathways.

For the NHS, delivering semaglutide at scale will require robust obesity‑and‑cardiovascular risk clinics, pharmacist‑ or nurse‑led titration services, and strong lifestyle‑support programmes; a pharmacist‑led GLP‑1 clinic in a cardiology service, for example, achieved 12.6% weight loss at six months with improvements in HbA1c, LDL, triglycerides and blood pressure when drugs were integrated with diet and activity counselling.

At the same time, ethical and public‑health concerns are emerging around off‑label or purely cosmetic use, drug shortages for people with diabetes, and media‑driven demand for “quick‑fix” weight‑loss injections, all of which can undermine rational resource allocation in publicly funded systems like the NHS

Semaglutide (Wegovy) for Obesity and Heart Disease | How a New Injection Could Reshape NHS Prevention Strategy

Recent Posts